Stryker (SYK)
(Real Time Quote from BATS)
$348.41 USD
+2.42 (0.70%)
Updated Jun 6, 2024 03:20 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
SYK 348.41 +2.42(0.70%)
Will SYK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SYK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SYK
Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System
Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market
SYK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
Other News for SYK
Bank of America Securities Reaffirms Their Buy Rating on Stryker (SYK)
Stifel sees S&P 500 dropping 10% with sticky inflation preventing Fed rate cuts
Stryker releases LIFEPAK 35 monitor/defibrillator
Needham medtech/diagnostic analyst holds analyst/industry conference call
Stryker’s Strategic Acquisition of Artelon Strengthens Market Position: A Buy Rating Endorsement